Brookline Capital Management Stock Recommendations and Price Targets

This is a list of recent ratings by Brookline Capital Management.

Date	Company Name	Action	Current Price	Price Target	Rating	Impact on Share Price
12/10/2024	CRVO CervoMed	Downgrade	$2.00		Strong-Buy ➝ Hold	N/A
12/5/2024	YMAB Y-mAbs Therapeutics	Initiated Coverage	$10.00	$17.00	Buy	N/A
12/4/2024	YMAB Y-mAbs Therapeutics	Upgrade	$10.00		Strong-Buy	N/A
11/20/2024	PALI Palisade Bio	Initiated Coverage	$2.00	$38.00	Buy	N/A
11/15/2024	EYEN Eyenovia	Reiterated Rating	$0.00		Buy ➝ Hold	N/A
11/13/2024	SYRS Syros Pharmaceuticals	Reiterated Rating	$0.00		Buy ➝ Hold	N/A
10/14/2024	COCH Envoy Medical	Initiated Coverage	$2.00	$9.00	Buy	Low
10/2/2024	VRCA Verrica Pharmaceuticals	Reiterated Rating	$1.00		Buy ➝ Hold	High
9/12/2024	ONCT Oncternal Therapeutics	Reiterated Rating	$1.00		Buy ➝ Hold	N/A
8/22/2024	OSTX OS Therapies	Upgrade	$5.00		Strong-Buy	Low
7/22/2024	IBIO iBio	Initiated Coverage	$2.00	$3.60	Buy	Low
7/22/2024	MEIP MEI Pharma	Downgrade	$3.00		Strong-Buy ➝ Hold	Low
7/9/2024	UNCY Unicycive Therapeutics	Upgrade	$1.00		Strong-Buy	Low
7/8/2024	CRVO CervoMed	Initiated Coverage	$2.00	$63.00	Buy	Low
6/7/2024	SABS SAB Biotherapeutics	Initiated Coverage	$4.00	$8.00	Buy	Low
5/30/2024	FBRX Forte Biosciences	Initiated Coverage	$20.00	$4.00	Buy	Low
5/30/2024	ALRN Aileron Therapeutics	Upgrade	$2.00		Strong-Buy	Low
5/15/2024	DARE Daré Bioscience	Upgrade	$3.00	$36.00	Hold ➝ Buy	Low
4/17/2024	DARE Daré Bioscience	Downgrade	$3.00		Buy ➝ Hold	N/A
4/5/2024	IMUX Immunic	Reiterated Rating	$1.00	$10.00	Buy	Low
3/4/2024	ATBPF Antibe Therapeutics	Downgrade	$0.00		Buy ➝ Hold	Low
3/4/2024	ATE Antibe Therapeutics	Downgrade	C$0.00		Buy ➝ Hold	N/A
2/28/2024	ANVS Annovis Bio	Downgrade	$5.00	$9.00	Buy ➝ Hold	Low
1/25/2024	OTLK Outlook Therapeutics	Upgrade	$1.00	$31.40	Hold ➝ Buy	Low
12/19/2023	CYCC Cyclacel Pharmaceuticals	Downgrade	$0.00		Buy ➝ Hold	Low
12/7/2023	HEPA Hepion Pharmaceuticals	Downgrade	$1.00		Buy ➝ Hold	Low
12/4/2023	ONCT Oncternal Therapeutics	Upgrade	$1.00	$40.00	Hold ➝ Buy	Low
11/30/2023	LNTH Lantheus	Initiated Coverage	$93.00	$100.00	Buy	Low
11/15/2023	SQZB SQZ Biotechnologies	Downgrade	$0.00		Buy ➝ Hold	Low
11/10/2023	ANVS Annovis Bio	Reiterated Rating	$5.00	$35.00	Buy	Low
10/30/2023	GNLX Genelux	Upgrade	$2.00		Hold ➝ Buy	Low
10/17/2023	EYEN Eyenovia	Initiated Coverage	$0.00	$8.00	Buy	Low
10/12/2023	EDSA Edesa Biotech	Reiterated Rating	$2.00	$57.00	Buy ➝ Buy	Low
9/6/2023	PROC Procaps Group	Downgrade	$4.00	$4.50	Buy ➝ Hold	Low
8/30/2023	OTLK Outlook Therapeutics	Downgrade	$1.00		Buy ➝ Hold	Low
8/14/2023	ATBPF Antibe Therapeutics	Reiterated Rating	$0.00		Buy	Low
6/5/2023	BLPH Bellerophon Therapeutics	Downgrade	$0.00		Buy ➝ Hold	Low
4/3/2023	ONCT Oncternal Therapeutics	Downgrade	$1.00		Buy ➝ Hold	Low
3/9/2023	ONCT Oncternal Therapeutics	Reiterated Rating	$1.00		Buy	Low
2/14/2023	DARE Daré Bioscience	Reiterated Rating	$3.00		Buy	Low
1/31/2023	HEPA Hepion Pharmaceuticals	Reiterated Rating	$1.00		Buy	Low
1/12/2023	ECOR electroCore	Reiterated Rating	$14.00		Buy	N/A
12/7/2022	CWBR CohBar	Downgrade	$1.00		Buy ➝ Hold	Low
11/14/2022	IMNN Imunon	Reiterated Rating	$1.00		Buy	Low
10/3/2022	ADIL Adial Pharmaceuticals	Reiterated Rating	$1.00		Buy	Low
10/3/2022	DRMA Dermata Therapeutics	Reiterated Rating	$1.00		Buy	Low
10/3/2022	EDSA Edesa Biotech	Reiterated Rating	$2.00		Buy	Low
10/3/2022	OTLK Outlook Therapeutics	Reiterated Rating	$1.00		Buy	Low
10/3/2022	CYCC Cyclacel Pharmaceuticals	Reiterated Rating	$0.00		Buy	Low
10/3/2022	MNPR Monopar Therapeutics	Reiterated Rating	$31.00		Buy	Low
10/3/2022	IMNN Imunon	Reiterated Rating	$1.00		Buy	Low
10/3/2022	VXRT Vaxart	Reiterated Rating	$1.00		Buy	Low
10/3/2022	CWBR CohBar	Reiterated Rating	$1.00		Buy	Low
10/3/2022	LSTA Lisata Therapeutics	Reiterated Rating	$3.00		Buy	Low
8/15/2022	ATE Antibe Therapeutics	Reiterated Rating	C$0.00		Buy	N/A
8/10/2022	ARCT Arcturus Therapeutics	Reiterated Rating	$16.00		Buy	Low
6/30/2022	ATBPF Antibe Therapeutics	Reiterated Rating	$0.00		Buy	N/A
5/18/2022	VERU Veru	Boost Price Target	$1.00	$29.00 ➝ $31.00	Buy ➝ Buy	Medium
4/4/2022	BLPH Bellerophon Therapeutics	Lower Price Target	$0.00	$26.00 ➝ $19.00		Low
3/10/2022	VRCA Verrica Pharmaceuticals	Reiterated Rating	$1.00		Buy	Medium
3/7/2022	NTLA Intellia Therapeutics	Upgrade	$13.00	$91.00	Hold ➝ Buy	High
2/14/2022	CRBU Caribou Biosciences	Reiterated Rating	$2.00		Buy	Medium
2/14/2022	CRSP CRISPR Therapeutics	Reiterated Rating	$45.00	$143.00	Buy	High
2/14/2022	NTLA Intellia Therapeutics	Reiterated Rating	$13.00		Buy	Low
2/3/2022	BCDA BioCardia	Reiterated Rating	$2.00		Buy	High
2/1/2022	ICCM IceCure Medical	Reiterated Rating	$1.00		Buy	Low
1/26/2022	HEPA Hepion Pharmaceuticals	Reiterated Rating	$1.00		Buy	Low
1/19/2022	DARE Daré Bioscience	Reiterated Rating	$3.00		Buy	High